 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareCROI 2010 Newsroom: HIV Treatment
- CROI 2010 Wrap-Up: Complications of HIV and Its Treatment (March 30, 2010)
A discussion with Pablo Tebas, M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - CROI 2010 Wrap-Up: The Evolution of Antiretroviral Therapy (March 8, 2010)
A discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - CROI 2010 Wrap-Up: The HIV Drug Development Pipeline (March 8, 2010)
A discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Mixed Findings on Value of Brain-Penetrating Antiretroviral Scores (February 22, 2010)
From National AIDS Treatment Advocacy Project - Many Patients Diagnosed With HIV Today Will Have Normal Life Expectancies, European Studies Find (February 22, 2010)
From aidsmap.com - News Outlets Examine Use of ART, Microbicide Development Presented at Conference (February 22, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation - Studies Confirm That Drugs That Penetrate Brain Control HIV Better and Improve Symptoms of Brain Impairment (February 21, 2010)
From aidsmap.com - Fast ART in Late Disease Means Slower Progression in Europe and Canada (February 20, 2010)
From National AIDS Treatment Advocacy Project - Life Expectancy Approaches Normal in Dutch Without HIV Symptoms (February 20, 2010)
From National AIDS Treatment Advocacy Project - Three Years With More Than 500 CD4s Normalizes Mortality in HIV-Positive Men (February 20, 2010)
From National AIDS Treatment Advocacy Project - The Once and Future King: What Will Replace Atripla Atop the First-Line HIV Treatment Realm? (Feb. 19, 2010; 3:39 p.m. Pacific Time)
A blog entry from CROI 2010 by Gerald Pierone Jr., M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Detachable Needles on Syringes Promote Hepatitis C Transmission, Study Says (February 19, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - U.S. Company Virxsys Says Using AIDS to Fight AIDS (February 19, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Immune Restoration in DART Study: Late Start Means Low CD4 Count for Years (February 19, 2010)
From aidsmap.com - Treatment Drive in British Columbia Produces Modest Declines in Diagnoses and Viral Loads (February 19, 2010)
From aidsmap.com - Low-Level Viremia Quadruples Death Risk in Canadian Cohort Study (February 18, 2010)
From National AIDS Treatment Advocacy Project - Older Age, Lower CD4 Nadir, NNRTI Use Predict Slow CD4 Recovery in ATHENA (February 18, 2010)
From National AIDS Treatment Advocacy Project - Vicriviroc Does Not Outdo Placebo Regimen in Phase 3 Trials (February 18, 2010)
From National AIDS Treatment Advocacy Project - Maraviroc Does Not Boost Stalled CD4s in Virologically Suppressed People (February 18, 2010)
From National AIDS Treatment Advocacy Project - QUAD Four-in-One Pill as Strong as Atripla, but a Kidney Concern Arises (February 18, 2010)
From National AIDS Treatment Advocacy Project - Elvitegravir "Quad" Pill Performs Well, New Booster Cobicistat Works as Well as Ritonavir (February 18, 2010)
From aidsmap.com - New CCR5 Antagonist TBR-652 Shows Good Antiviral Activity in Early Study (February 18, 2010)
From aidsmap.com - CCR5 Antagonist Vicriviroc Fails to Surpass Potent Background Regimen (February 18, 2010)
From aidsmap.com - Once-Daily Darunavir Effective and Less Toxic Than Twice-Daily in Experienced Patients Without Prior Darunavir Resistance: ODIN (February 18, 2010)
From aidsmap.com - Increased Testing Leads to Decrease in Viral Load and Infections in San Francisco, and in Late Diagnosis in Washington (February 18, 2010)
From aidsmap.com - ACTG 5202: No Significant Difference in Time to Failure Between Kivexa and Truvada in Patients With Lower Viral Loads When Paired With Efavirenz or Atazanavir (February 18, 2010)
From aidsmap.com - The End of HIV Drug Development as We Know It? (Feb. 18, 2010; 1:45 p.m. Pacific Time)
A blog entry from CROI 2010 by Gerald Pierone Jr., M.D.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - The New Quad on the Block: Gilead's Four-Drug, Fixed-Dose Combination With a Novel Booster Sails Through Phase 2 Trials (Feb. 18, 2010; 1:15 a.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Why Vicriviroc Failed in Its Phase 3 Trials -- and What It May Mean for Future Studies in HIV Treatment-Experienced People (Feb. 17, 2010; 11:36 a.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Will CROI 2010 Provide HIV/AIDS Clinicians With More Questions Than Answers? (Feb. 16, 2010; 4:49 p.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.